Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation

• Status: Active, not recruiting
• Trial end date: 2022-06-07
• Target enrollment: 0
• Participant gender: All

Summary

In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the Non-valvular Atrial Fibrillation (NVAF) indication, Daiichi-Sankyo proposed this post-authorization safety study (PASS) to gain insight into the safety (bleeding, liver adverse events, all-cause mortality and other drug related adverse events) of edoxaban use in patients with NVAF who were not preselected.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daiichi Sankyo Inc.; Daiichi Sankyo, Inc.
• Collaborators: Hippocrates Research; IMS Health; ITEC Services; Quintiles, Inc.; SSS International Clinical Research GmBH
• Treatments: Edoxaban

Criteria

Inclusion Criteria:

• NVAF-patients treated with edoxaban according to Summary of Product Characteristics (SmPC).

• Written informed consent for participation in the study (ICF).

• Not simultaneously participating in any interventional study.

Exclusion Criteria:

• None